“Basic studies led to clinical and translational advances that no one could have predicted,” Robert Gallo writes of his work with interleukin-2.

Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.

Longevity clinics promise personalized health advice and cutting-edge tests. Now major hospitals are entering the business, at costs reaching $45,000 a year.

“Are we entering a world in which some (or all) Nobels will be awarded to Claude, ChatGPT, or their AI successors, rather than human scientists?” asks Jeffrey Flier.

Workers and employers are drowning in their health insurance premiums. The reason for that deluge: the health care industry’s high and inscrutable prices.

Ahead of this year's Nobel Prize announcements, STAT chatted with Mary-Claire King, who discovered the BRCA cancer mutations and is frequently mentioned in prize predictions.

In Washington, Eric Cantor will confront bipartisan backlash over rising health care costs.

Blockbuster GLP-1 drugs have transformed the lives of millions of people. Lately, they’re undergoing a makeover of their own.

Big shifts in health care policy could emerge depending on who wins the midterms, affecting hospitals and pharma companies.

“Arguing over whether someone died ‘with’ or ‘of’ a disease gets us stuck on the last thing that happened.” write two Unbiased Science scientists.

Heidi Overton, Trump's pick for FDA head, will face questions at a Senate hearing. Follow along with our live blog.

President Trump and his aides boasted that every U.S. state wanted to participate in a drug pricing initiative through Medicaid. Several states said they weren't sure yet.

A planned EO that would have greatly enhanced White House influence over grants at the NIH is “looking dead,” a source said.

Medicines for osteoporosis are grabbing the attention of the pharma industry, which has been incentivized by a long-awaited regulatory change.

Why an influential GOP health policy expert still backs $1 trillion in Medicaid cuts — and which policy target is next.

Two former FDA commissioners: Heidi Overton is the right pick in a difficult moment.

Research shows that integrative therapies reduce cancer-related pain, fatigue, anxiety, and nausea. Why won't insurance pay?

Several members of Congress voiced strong opposition about a reported plan to create a panel of political appointees to sign off on NIH grants

Shares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting.

Addiction clinics are seeing a surge in patients dependent on potent kratom and 7-OH products.

“We should be strengthening our investment in the NIH, not dismantling it,” writes Reed Jobs.

STAT's Alex Hogan sits down for an in-depth conversation with our new trust-in-science reporter, Nicholas Florko, on the latest episode of STATus Report.

"I know what it means to be searching for an explanation to what ails you, and a way to fix it," writes STAT's new trust-in-science reporter, Nicholas Florko.

Health secretary RFK Jr. returned to his roots in a keynote address at a conference hosted by the Children’s Health Defense, an anti-vaccine nonprofit he helped start.

Health secretary RFK Jr. returned to his roots in a keynote address at a conference hosted by the Children’s Health Defense, an anti-vaccine nonprofit he helped start.

The influential panel hasn't met in more than a year, after Kennedy canceled its meeting.

Scientists have made mice with half a brain, then filled them with human organoids — possibly opening new avenues for research but also raising ethical issues.

The rushed launch of a Medicare pilot to use AI for prior authorization led to delayed care in some instances, new documents reveal.

A federal judge halted a Trump administration plan to place a four-year cap on the kinds of visas used by graduate students and postdocs

RFK Jr. worked to distance himself from Children's Health Defense, the anti-vaccine group he once led. Now, he's delivering a keynote at CHD's conference.

Hospital leaders were excited about the Rural Health Transformation Fund until they saw the fine print.

The first wave of biotechs is nearing regulatory approval for psychedelic therapies, a class of treatments that appear to exert rapid benefits.

Platinum chemotherapy aged the liver cells of treated children, making them look more like adult liver cells and possibly raising the long-term risk of new tumors

Caspian Therapeutics, is launching with $50 million in financing to develop menin inhibitors for diabetes and other cardiometabolic diseases.

CEOs of the biggest AI companies have predicted the technology will “eliminate most cancer” and “improve treatment of most other ailments.” But nowhere better illustrates the challenge facing AI than ...

“As a medical student in a larger body, I have often been ostracized, othered, made to feel different, like I’ve invaded a secret society of thin people.”

“As a medical student in a larger body, I have often been ostracized, othered, made to feel different, like I’ve invaded a secret society of thin people.”

Tactical athletes, a category of people first recognized in the early 2000s, also need distinct kinds of health care.

Anthony Fauci is working on a book, we unpack Trump's latest drug pricing deals, and more from STAT's D.C. Diagnosis newsletter.

At a "practice of last resort," pediatricians prioritize allaying parents' vaccine concerns without hardline dismissals.

The House voted to pass a stopgap funding bill that, for now, blocks a White House proposal to give political appointees more control over research grants.

An NIH proposal to cap the number of research grants investigators can receive has drawn a mixed reception, the agency says.

With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the technology in other areas.

Marc Tessier-Lavigne released new details from his research and travel in an attempt to refute allegations in a new book that he published fraudulent results.

Kennedy has blamed others for declining vaccination rates, and downplayed the dangers of measles.

The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.